DEA Finalizes Prescription Opioid Anti-Diversion Policy
The DEA’s final rule was virtually identical to a proposed rule issued in April. It will formalize the agency's unofficial practice of examining how well drugmakers monitor suspicious opioid orders, and will thereby "encourage vigilance on the part of opioid manufacturers," according to a government announcement on Wednesday.
If drugmakers perform...
To view the full article, register now.